Intraneuronal dopamine-quinone synthesis: A review

被引:227
作者
Sulzer, David [1 ,2 ]
Zecca, Luigi [2 ,3 ]
机构
[1] Columbia Univ, New York State Psychiat Inst, Dept Neurol & Psychiat, New York, NY 10032 USA
[2] Columbia Univ, New York State Psychiat Inst, Dept Neurosci, New York, NY 10032 USA
[3] CNR, Inst Adv Biomed Technol, I-20090 Segrate, Italy
关键词
Neuromelanin; Parkinson's disease; Lewy bodies; Methamphetamine; Oxidative stress; VMAT; Substantia nigra; Tyrosinase;
D O I
10.1007/BF03033289
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Dopamine-quinone is synthesized by oxidation of the catechol ring of dopamine. If this occurs within the neuronal cytosol, the quinone may react with cytosolic components, particularly cysteine residues. In contrast, if quinone is produced within neuronal lysosomes it may provide the fundamental building block for neuromelanin. Since the population of neurons that die in Parkinson's disease are those that display obvious intralysosomal neuromelanin and since cytosolic dopamine-dependent oxyradical formation may underlie methamphetamine toxicity and other specific forms of neurodegeneration in dopaminergic neurons, it is important to elucidate the pathways leading to dopamine-quinone. Here we review pathways by which intracellular catechols may be oxidized to quinones, either enzymatically or via reduction of ferric iron or other metals. These metabolites can be adduced by cysteine, could underlie aberrant metabolism and ubiquitination pathways, may induce Lewy body formation, and mediate the synthesis of hydroxyl radical and oxyradical species. Finally, we suggest that by accumulating excess cytosolic catecholamine, neuromelanin synthesis may safely sequester quinones that would otherwise be produced in neuronal cytosol.
引用
收藏
页码:181 / 195
页数:15
相关论文
共 129 条
[41]   Degradation of oxidized proteins in mammalian cells [J].
Grune, T ;
Reinheckel, T ;
Davies, KJA .
FASEB JOURNAL, 1997, 11 (07) :526-534
[42]  
Haavik J, 1997, J NEUROCHEM, V69, P1720
[43]  
HASTINGS TG, 1995, J NEUROCHEM, V64, P919
[44]  
HASTINGS TG, 1994, J NEUROCHEM, V63, P1126
[45]   AN EARLY CYTOPLASMIC CHANGE BEFORE LEWY BODY MATURATION - AN ULTRASTRUCTURAL-STUDY OF THE SUBSTANTIA-NIGRA FROM AN AUTOPSY CASE OF JUVENILE PARKINSONISM [J].
HAYASHIDA, K ;
OYANAGI, S ;
MIZUTANI, Y ;
YOKOCHI, M .
ACTA NEUROPATHOLOGICA, 1993, 85 (04) :445-448
[46]   DOPAMINE, TREMOR, AND PARKINSONS-DISEASE [J].
HIRSCH, EC ;
MOUATT, A ;
FAUCHEUX, B ;
BONNET, AM ;
JAVOYAGID, F ;
GRAYBIEL, AM ;
AGID, Y .
LANCET, 1992, 340 (8811) :125-126
[47]  
Holtzman E, 1992, Curr Opin Neurobiol, V2, P607, DOI 10.1016/0959-4388(92)90026-H
[48]   Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly [J].
Ii, K ;
Ito, H ;
Tanaka, K ;
Hirano, A .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1997, 56 (02) :125-131
[49]   Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity [J].
Irizarry, MC ;
Growdon, W ;
Gomez-Isla, T ;
Newell, K ;
George, JM ;
Clayton, DF ;
Hyman, BT .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1998, 57 (04) :334-337
[50]   COVALENT BINDING OF CATECHOLS TO PROTEINS THROUGH THE SULFHYDRYL-GROUP [J].
ITO, S ;
KATO, T ;
FUJITA, K .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (09) :1707-1710